Editorials: Controversies in Family Medicine
Should Family Physicians Follow the New ACC/AHA Cholesterol Treatment Guideline? Not Completely: Why It Is Right to Drop LDL-C Targets, but Wrong to Recommend Statins at a 7.5% 10-Year Risk
Am Fam Physician. 2014 Aug 15;90(4):223-224.
Related editorial: Should Family Physicians Follow the New ACC/AHA Cholesterol Treatment Guideline? Yes: Implementing the New ACC/AHA Cholesterol Guideline Will Improve Cardiovascular Outcomes
Related Practice Guidelines: ACC/AHA Release Updated Guidelines on the Treatment of Blood Cholesterol to Reduce ASCVD Risk
This is one in a series of pro/con editorials discussing controversial issues in family medicine.
The new American College of Cardiology/American Heart Association (ACC/AHA) cholesterol treatment guideline moved clinical practice in the right direction, but not far enough.1 I applaud the ACC/AHA committee for dropping low-density-lipoprotein cholesterol (LDL-C) target levels and basing recommendations on a patient's risk of cardiovascular events. However, the committee's recommendations should have paid more attention to the inherent uncertainties in risk estimates and the importance of individual patient circumstances and preferences.
I want to focus on the ACC/AHA recommendation that is most important for primary care physicians: to recommend a statin for primary cardiovascular prevention when a person's 10-year risk of having a heart attack or stroke is greater than 7.5%, and to not otherwise treat LDL-C level elevations unless they are greater than 190 mg per dL (4.92 mmol per L).1
Why Drop LDL-C Target Levels?
We now have high-quality clinical trial evidence showing that the relative benefits or harms of statin use do not vary based on a person's LDL-C level.2,3 Furthermore, multiple clinical trials have found no benefit from adding a second lipid-lowering medication to a statin, so the new guideline does not recommend using a second cholesterol medication in pursuit of LDL-C target levels.1 Indeed, the concept of treating to target levels is not supported by evidence from randomized trials.4–6 A treat-to-target approach ignores how other patient factors impact expected risks and benefits, and has the possible downside of promoting poly-pharmacy by not considering the amount of potential treatment benefit and harm. In short, surrogate treatment target levels distract us from the central tenet of good decision making—weighing the chances of benefits against the chances of harms. from randomized trials.4–6 A treat-to-target approach ignores how other patient factors impact expected risks and benefits, and has the possible downside of promoting poly-pharmacy by not considering the amount of potential treatment benefit and harm. In short, surrogate treatment target levels distract us from the central tenet of good decision making—weighing the chances of benefits against the chances of harms.
Why Treat Based on Overall Cardiovascular Risk?
To date, the evidence suggests that a statin's relative risk reduction is similar across lower- and higher-risk primary prevention patients younger than 70 years.7,8 This means that a person with a 10-year risk of 20% receives about the same relative reduction in heart attacks as someone with a risk of 10%, but the former patient receives about twice the absolute benefit as the latter patient.4 Therefore, the 10-year absolute benefit for any individual without known cardiovascular disease is best estimated by multiplying his or her overall cardiovascular risk by the average relative risk reduction of a particular statin dose.
A Personal Example of Patient Preferences
I am 58 years old, and my 10-year cardiovascular risk is about 7% to 8%, but I have decided to not yet take a statin. Why? The statin dose recommended by the ACC/AHA guideline for persons like me (40 mg of simvastatin [Zocor] or 10 to 20 mg of atorvastatin [Lipitor]) has about a 35% to 40% relative risk reduction,4,7 meaning that it would reduce my 10-year risk of having a heart attack to about 4% to 5% (roughly a three in 100 chance of preventing a heart attack over the next 10 years). To some, this is probably high enough to warrant starting a statin, but I am willing to accept a slightly higher chance of a heart attack (most of which are mild in my age group) over the next five years instead of starting a medication for which we currently lack good long-term safety data. If my 10-year cardiovascular risk were closer to 15%, a reduction to roughly 8% seems well worth the risks of taking a daily statin. However, I am happy to prescribe a statin earlier to my patients if they wish.
When Should Physicians Prescribe a Statin for Primary Prevention?
My biggest criticism of the new guideline is that it does not acknowledge a specific gray zone—a range in which the potential benefits and harms of a statin make the “right decision” predominantly a matter of individual patient circumstances and preferences.9,10 It may be reasonable to set 7.5% as a starting point for discussion (e.g., for every 33 patients treated for 10 years, roughly one heart attack will be prevented [i.e., number needed to treat = 33]). But these risks and benefits are estimates with a nontrivial margin of error (different risk calculator estimates can vary by 20% to 30%). The guideline does note that shared decision making should be used, but it provides no clear direction on when statins should be recommended rather than just discussed. Specifying a gray zone, such as a 10-year risk of 7.5% to 12.5%, could be a solution. In this range, treatment is more appropriate for those who worry more about heart attacks and less appropriate for those who worry more about adverse events from medication use. To avoid polypharmacy, one might be more likely to recommend a statin in the latter group when a patient is taking two medications vs. 15 medications.
I have heard many suggest that such nuances are beyond the abilities of primary care physicians, but I strongly disagree. Those who make guidelines and performance measures need to stop behaving as if primary care physicians need rigid rules for every decision, even those that are close calls.9,10 They need to recognize that for virtually every decision in life, there is a gray range in which the right decision is purely one of personal preference, a range in which they should defer to the primary care physicians who actually know the patient. The ACC/AHA committee did a great job of moving us to a measure that better estimates the chance that our patients benefit from a statin (overall cardiovascular risk), but they should now revise their guideline to specify a range in which the decision to start a statin should be tailored to the individual and not recommended by a central committee.
The opinions above are the author's and do not represent those of the U.S. Department of Veterans Affairs or the University of Michigan.
editor's note: Dr. Hayward is supported in part by the U.S. Department of Veterans Affairs Health Services Research & Development's Quality Enhancement Research Initiative (QUERI DIB 98–001) and by the Measurement Core of the Michigan Center for Diabetes Translational Research (NIDDK of the National Institutes of Health [P60 DK-20572]).
editor's note: The AAFP endorsed the ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults with “qualifications” in June 2014. The qualifications include a concern that the cardiovascular disease risk assessment tool has not been validated and may overestimate risk with a cutoff of 7.5% leading to greater statin use; a note that many of the recommendations were based on expert opinion; and mention of conflict of interest in nearly one-half of the panel members.—SUMI SEXTON, MD, Associate Medical Editor, American Family Physician
REFERENCESshow all references
1. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 suppl2):S1–S45....
2. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Black-well L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
3. Hayward RA, Hofer TP, Vijan S. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med. 2006;145(7):520–530.
4. Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Optimizing statin treatment for primary prevention of coronary artery disease [published correction appears in Ann Intern Med. 2011;154(12):848]. Ann Intern Med. 2010;152(2):69–77.
5. Hayward RA, Krumholz HM. Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health. Circ Cardiovascular Qual Outcomes. 2012;5(1):2–5.
6. Sussman J, Vijan S, Hayward R. Using benefit-based tailored treatment to improve the use of antihypertensive medications. Circulation. 2013;128(21):2309–2317.
7. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–590.
8. Ridker PM, Danielson E, Fonseca FA, et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.
9. Quanstrum KH, Hayward RA. Lessons from the mammography wars. N Engl J Med. 2010;363(11):1076–1079.
10. Kerr EA, Hayward RA. Patient-centered performance management: enhancing value for patients and health care systems. JAMA. 2013;310(2):137–138.
Copyright © 2014 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Aug 1, 2020
Access the latest issue of American Family Physician